Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MIKE CUSNIR

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1962490631
CMS profile
88663
Location
MIAMI BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$20,154.30

380 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Sirtex Medical Inc $5,200.00 2
Ipsen Biopharmaceuticals, Inc $4,561.30 8
BeiGene USA, Inc. $1,634.52 16
AstraZeneca Pharmaceuticals LP $951.14 20
ARRAY BIOPHARMA INC $769.38 8
Celgene Corporation $662.27 28
PFIZER INC. $630.69 33
Janssen Biotech, Inc. $546.25 47
GENZYME CORPORATION $477.27 11
Novartis Pharmaceuticals Corporation $420.53 27
Regeneron Healthcare Solutions, Inc. $271.02 8
Bayer Healthcare Pharmaceuticals Inc. $269.79 10
Tempus AI, Inc $268.79 8
Incyte Corporation $247.29 7
Merck Sharp & Dohme LLC $241.74 12
Eisai Inc. $234.41 11
ABBVIE INC. $216.82 9
Astellas Pharma US Inc $189.47 8
Takeda Pharmaceuticals U.S.A., Inc. $162.77 8
Daiichi Sankyo Inc. $158.12 8
Mirati Therapeutics, Inc. $148.14 8
SpringWorks Therapeutics, Inc. $141.29 7
Boehringer Ingelheim Pharmaceuticals, Inc. $135.95 5
E.R. Squibb & Sons, L.L.C. $128.47 7
Gilead Sciences, Inc. $126.26 2
Sumitomo Pharma America, Inc. $119.89 5
SEAGEN INC. $98.65 1
EMD Serono, Inc. $97.29 5
Deciphera Pharmaceuticals Inc. $92.83 4
TAIHO ONCOLOGY, INC. $88.12 4
GlaxoSmithKline, LLC. $79.14 4
JAZZ PHARMACEUTICALS INC. $73.15 3
Adaptive Biotechnologies Corporation $58.99 3
Agios Pharmaceuticals, Inc. $58.16 3
Myriad Genetic Laboratories, Inc. $57.70 3
Pharmacosmos Therapeutics Inc. $54.94 3
Exelixis Inc. $54.52 3
SERVIER PHARMACEUTICALS LLC $48.50 2
RECORDATI_RARE_DISEASES_INC. $40.87 2
SOBI, INC $39.25 2
Karyopharm Therapeutics Inc. $35.23 2
Alexion Pharmaceuticals, Inc. $33.29 1
Stemline Therapeutics Inc. $32.19 2
Dendreon Pharmaceuticals LLC $29.80 1
Aveo Pharmaceuticals, Inc. $26.60 1
Janssen Pharmaceuticals, Inc $26.12 2
Genentech USA, Inc. $21.90 1
SUN PHARMACEUTICAL INDUSTRIES INC. $21.00 1
TerSera Therapeutics LLC $20.00 1
Rigel Pharmaceuticals, Inc. $19.52 1
Lilly USA, LLC $18.00 1
Blueprint Medicines Corporation $14.97 1

Page 8 of 8; records 351–380 of 380 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MIKE CUSNIR

NPI 1962490631 · CMS profile ID 88663

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

MIAMI BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 8 of 8; records 351–380 of 380 matching records. This page contains 30 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962490631?year=2024&recipient=provider&page=8#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MIKE CUSNIR, NPI 1962490631, CMS profile ID 88663. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 8; records 351–380 of 380 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962490631?year=2024&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MIKE CUSNIR, NPI 1962490631, CMS profile ID 88663. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 8; records 351–380 of 380 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962490631?year=2024&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MIKE CUSNIR, NPI 1962490631, CMS profile ID 88663, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 8 of 8; records 351–380 of 380 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1962490631?year=2024&recipient=provider&page=8#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

380 matching records · $20,154.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 380 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 351–380 of 380.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $26.8401/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141560850 CMS
Janssen Biotech, Inc. $23.2901/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078454585 CMS
GENZYME CORPORATION $28.1901/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139689884 CMS
Janssen Biotech, Inc. $5.9101/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078454730 CMS
ARRAY BIOPHARMA INC $630.0001/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131311091 CMS
AstraZeneca Pharmaceuticals LP $24.6701/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104517608 CMS
Celgene Corporation $17.3001/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101184599 CMS
AstraZeneca Pharmaceuticals LP $18.8301/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105881862 CMS
Bayer Healthcare Pharmaceuticals Inc. $107.9501/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086122316 CMS
BeiGene USA, Inc. $13.7701/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120858203 CMS
Janssen Biotech, Inc. $6.6201/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078454118 CMS
PFIZER INC. $20.6401/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131106917 CMS
BeiGene USA, Inc. $15.6401/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120858205 CMS
Adaptive Biotechnologies Corporation $20.7201/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150261096 CMS
Ipsen Biopharmaceuticals, Inc $820.0001/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091951501 CMS
Janssen Biotech, Inc. $18.5201/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078454611 CMS
Mirati Therapeutics, Inc. $22.5801/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117176735 CMS
AstraZeneca Pharmaceuticals LP $31.4101/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105795094 CMS
Incyte Corporation $29.5401/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141207173 CMS
Celgene Corporation $30.5701/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101184603 CMS
EMD Serono, Inc. $20.0001/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120224553 CMS
PFIZER INC. $14.5201/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131158218 CMS
TAIHO ONCOLOGY, INC. $19.9301/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137940902 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.4901/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144955793 CMS
PFIZER INC. $16.7501/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131302181 CMS
Eisai Inc. $26.2501/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110766851 CMS
Janssen Biotech, Inc. $18.2501/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078454389 CMS
PFIZER INC. $13.8601/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131296081 CMS
Merck Sharp & Dohme LLC $17.7701/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141823421 CMS
Novartis Pharmaceuticals Corporation $15.4701/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086722397 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34,968.03 459
PY2020 $14,378.24 259
PY2021 $28,912.07 302
PY2022 $35,124.83 304
PY2023 $31,038.71 324
PY2024 $20,154.30 380
PY2025 $16,779.28 360

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $554,620.22 87
PY2024 Principal investigator $514,545.35 83
PY2023 Principal investigator $254,771.60 107
PY2022 Principal investigator $174,461.99 49
PY2021 Principal investigator $95,929.81 71
PY2020 Principal investigator $86,337.27 73
PY2019 Principal investigator $126,177.02 70

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

87 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Rigel Pharmaceuticals, Inc. $3,975.00 12/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
C-906289-002 No dispute reported 06/30/2026 1249029789
Principal investigator 1 Incyte Corporation $1,250.00 12/12/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) No dispute reported 06/30/2026 1240477645
Principal investigator 1 Incyte Corporation $313.00 12/12/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) No dispute reported 06/30/2026 1240477648
Principal investigator 1 Incyte Corporation $313.00 12/12/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) No dispute reported 06/30/2026 1240477653
Principal investigator 1 PFIZER INC. $5,032.00 11/25/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228709004
Principal investigator 1 Janssen Research & Development, LLC $860.00 11/10/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175390845
Principal investigator 1 Janssen Research & Development, LLC $610.00 10/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175390857
Principal investigator 1 TAIHO ONCOLOGY, INC. $3,276.98 10/15/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. No dispute reported 06/30/2026 1211415411
Principal investigator 1 PFIZER INC. $315.00 10/14/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228709179
Principal investigator 1 PFIZER INC. $3,100.00 10/14/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228709181
Principal investigator 1 Genmab U.S., Inc. $380.00 10/09/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235925990
Principal investigator 1 Genmab U.S., Inc. $3,378.75 10/09/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235925996
Principal investigator 1 Incyte Corporation $80.82 10/06/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) No dispute reported 06/30/2026 1240477641
Principal investigator 1 Incyte Corporation $53.88 10/06/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) No dispute reported 06/30/2026 1240477657
Principal investigator 1 PFIZER INC. $10,940.00 09/22/2025 Non-covered Recipient Entity
Mount Sinai Comprehensive Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718483
Principal investigator 1 PFIZER INC. $32,997.51 09/22/2025 Non-covered Recipient Entity
Mount Sinai Comprehensive Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718600
Principal investigator 1 Exelixis Inc. $567.00 09/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222377274
Principal investigator 1 PFIZER INC. $8,865.00 09/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A PHASE 2 RANDOMIZED OPENLABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600EMUTANT MSI HDMMR METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228710844
Principal investigator 1 PFIZER INC. $32,997.51 09/19/2025 Non-covered Recipient Entity
Mount Sinai Comprehensive Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717337
Principal investigator 1 PFIZER INC. $10,940.00 09/19/2025 Non-covered Recipient Entity
Mount Sinai Comprehensive Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717339
Principal investigator 1 Iovance Biotherapeutics, Inc. $40,393.84 09/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
NCT02360579 No dispute reported 06/30/2026 1252498107
Principal investigator 1 Iovance Biotherapeutics, Inc. $625.00 09/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
NCT02360579 No dispute reported 06/30/2026 1252498109
Principal investigator 1 Iovance Biotherapeutics, Inc. $9,695.00 09/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
NCT02360579 No dispute reported 06/30/2026 1252498111
Principal investigator 1 Iovance Biotherapeutics, Inc. $500.00 09/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
NCT02360579 No dispute reported 06/30/2026 1252498113
Principal investigator 1 Iovance Biotherapeutics, Inc. $250.00 09/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
NCT02360579 No dispute reported 06/30/2026 1252498115
Principal investigator 1 Janssen Research & Development, LLC $1,105.00 09/12/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175390841
Principal investigator 1 Incyte Corporation $10.80 09/09/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) No dispute reported 06/30/2026 1240477621
Principal investigator 1 Incyte Corporation $21.40 09/09/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) No dispute reported 06/30/2026 1240477624
Principal investigator 1 Incyte Corporation $53.88 09/09/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) No dispute reported 06/30/2026 1240477629
Principal investigator 1 Incyte Corporation $10.80 09/09/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) No dispute reported 06/30/2026 1240477632
Principal investigator 1 Incyte Corporation $10.80 09/09/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) No dispute reported 06/30/2026 1240477637
Principal investigator 1 Merck Sharp & Dohme LLC $1,560.42 08/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1,2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers No dispute reported 06/30/2026 1232932890
Principal investigator 1 Genmab U.S., Inc. $1,160.00 08/26/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235925986
Principal investigator 1 PFIZER INC. $17,961.00 08/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228709006
Principal investigator 1 TAIHO ONCOLOGY, INC. $3,989.38 08/06/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. No dispute reported 06/30/2026 1211416848
Principal investigator 1 PFIZER INC. $4,562.50 08/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A PHASE 2 RANDOMIZED OPENLABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600EMUTANT MSI HDMMR METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228710846
Principal investigator 1 Rigel Pharmaceuticals, Inc. $850.00 08/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
C-906289-002 No dispute reported 06/30/2026 1249029793
Principal investigator 1 Rigel Pharmaceuticals, Inc. $625.00 07/25/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
C-906289-002 No dispute reported 06/30/2026 1249030053
Principal investigator 1 PFIZER INC. $2,890.00 07/21/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228709091
Principal investigator 1 PFIZER INC. $1,564.00 07/21/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228709094
Principal investigator 1 Gilead Sciences, Inc. $281.25 07/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1229211829
Principal investigator 1 TAIHO ONCOLOGY, INC. $7,479.00 07/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. No dispute reported 06/30/2026 1211419659
Principal investigator 1 Mirati Therapeutics, Inc. $1,331.00 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530001
Principal investigator 1 PFIZER INC. $4,280.00 06/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228709454
Principal investigator 1 PFIZER INC. $1,564.00 06/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228710684
Principal investigator 1 Janssen Research & Development, LLC $3,780.00 06/27/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175390835
Principal investigator 1 Janssen Research & Development, LLC $2,640.00 06/27/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175391020
Principal investigator 1 Novocure Inc. $1,875.00 06/26/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856335
Principal investigator 1 PFIZER INC. $20,711.26 06/25/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228711012
Principal investigator 1 TAIHO ONCOLOGY, INC. $452.50 06/24/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. No dispute reported 06/30/2026 1211419665
Principal investigator 1 PFIZER INC. $625.00 06/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228709274
Principal investigator 1 PFIZER INC. $2,267.00 06/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228709276
Principal investigator 1 PFIZER INC. $495.00 06/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228710360
Principal investigator 1 TAIHO ONCOLOGY, INC. $7,479.00 06/13/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. No dispute reported 06/30/2026 1211417513
Principal investigator 1 PFIZER INC. $26,328.00 06/09/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228709278
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,817.08 06/05/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. No dispute reported 06/30/2026 1211416122
Principal investigator 1 Rigel Pharmaceuticals, Inc. $15,639.14 06/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
C-906289-002 No dispute reported 06/30/2026 1249029941
Principal investigator 1 Janssen Research & Development, LLC $16,340.00 05/29/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175390983
Principal investigator 1 Janssen Research & Development, LLC $31,601.00 05/29/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175390996
Principal investigator 1 Janssen Research & Development, LLC $7,490.00 05/29/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175391080
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,250.00 05/28/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. No dispute reported 06/30/2026 1211419661
Principal investigator 1 Mirati Therapeutics, Inc. $1,331.00 05/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236529997
Principal investigator 1 Exelixis Inc. $1,637.10 05/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222377272
Principal investigator 1 TAIHO ONCOLOGY, INC. $452.50 05/15/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. No dispute reported 06/30/2026 1211418943
Principal investigator 1 Genmab U.S., Inc. $1,250.00 05/08/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235925982
Principal investigator 1 TAIHO ONCOLOGY, INC. $14,633.46 05/08/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. No dispute reported 06/30/2026 1211419663
Principal investigator 1 PFIZER INC. $10,940.00 04/15/2025 Non-covered Recipient Entity
Mount Sinai Comprehensive Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228834858
Principal investigator 1 PFIZER INC. $10,940.00 04/14/2025 Non-covered Recipient Entity
Mount Sinai Comprehensive Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228822912
Principal investigator 1 PFIZER INC. $1,050.00 04/07/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228710682
Principal investigator 1 PFIZER INC. $2,820.00 03/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228709096
Principal investigator 1 PFIZER INC. $10,940.00 03/27/2025 Non-covered Recipient Entity
Mount Sinai Comprehensive Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228834845
Principal investigator 1 PFIZER INC. $32,997.51 03/27/2025 Non-covered Recipient Entity
Mount Sinai Comprehensive Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228834853
Principal investigator 1 PFIZER INC. $10,940.00 03/26/2025 Non-covered Recipient Entity
Mount Sinai Comprehensive Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228822831
Principal investigator 1 PFIZER INC. $32,997.51 03/26/2025 Non-covered Recipient Entity
Mount Sinai Comprehensive Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228822917
Principal investigator 1 Exelixis Inc. $6,807.60 03/21/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222377270
Principal investigator 1 Iovance Biotherapeutics, Inc. $900.00 03/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
NCT02360579 No dispute reported 06/30/2026 1252496833
Principal investigator 1 PFIZER INC. $437.50 03/13/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228709177
Principal investigator 1 PFIZER INC. $13,075.20 03/13/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228711014
Principal investigator 1 TAIHO ONCOLOGY, INC. $7,479.00 03/13/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. No dispute reported 06/30/2026 1211417511
Principal investigator 1 TAIHO ONCOLOGY, INC. $17,022.54 03/06/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. No dispute reported 06/30/2026 1211416120
Principal investigator 1 Genmab U.S., Inc. $3,100.00 02/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235925978
Principal investigator 1 Exelixis Inc. $3,373.20 01/24/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222377268
Principal investigator 1 Genmab U.S., Inc. $580.00 01/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235925964
Principal investigator 1 Genmab U.S., Inc. $625.00 01/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235925971
Principal investigator 1 Novocure Inc. $900.00 01/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856583
Principal investigator 1 Genmab U.S., Inc. $3,050.00 01/09/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235925967
Principal investigator 1 Genmab U.S., Inc. $531.60 01/09/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235925974